Adalimumab for Ocular Inflammation

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate adalimumab as an immunomodulatory treatment for non-infectious ocular inflammatory diseases. Methods: Characteristics of patients treated with adalimumab were abstracted in a standardized chart review. Main outcomes measured were control of inflammation, corticosteroid-sparing effect, and visual acuity. Results: In total, 32 patients with ocular inflammation were treated with adalimumab. The most common ophthalmic diagnoses were anterior uveitis, occurring in 15 patients (47%), and scleritis, occurring in 9 patients (28%). At 6 months of therapy, among 15 eyes with active inflammation, 7 (47%) became completely inactive, and oral prednisone was reduced to ≤10 mg/day in 2 of 4 patients (50%). On average, visual acuity decreased by 0.13 lines during the first 6 months of treatment. Adalimumab was discontinued because of lack of effectiveness in four patients within 6 months. Conclusions: Adalimumab was moderately effective in controlling inflammation in a group of highly pre-treated cases of ocular inflammatory disease.

Original languageEnglish (US)
Pages (from-to)405-412
Number of pages8
JournalOcular Immunology and Inflammation
Volume25
Issue number3
DOIs
StatePublished - May 4 2017

    Fingerprint

Keywords

  • Adalimumab
  • Humira
  • TNF-α antibody
  • ocular inflammatory disease
  • scleritis
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group (2017). Adalimumab for Ocular Inflammation. Ocular Immunology and Inflammation, 25(3), 405-412. https://doi.org/10.3109/09273948.2015.1134581